Euroapi SAS (EAPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Euroapi SAS (EAPI) has a cash flow conversion efficiency ratio of 0.138x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€108.40 Million ≈ $126.73 Million USD) by net assets (€788.00 Million ≈ $921.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Euroapi SAS's balance sheet to measure how much of total assets are equity-financed.
Euroapi SAS - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Euroapi SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check EAPI cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Euroapi SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Euroapi SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jochu Technology Co Ltd
TW:3543
|
0.002x |
|
Tile Shop Holdings Inc
NASDAQ:TTSH
|
-0.063x |
|
AVer Information Inc
TW:3669
|
0.019x |
|
Asuransi Multi Artha Guna Tbk PT
JK:AMAG
|
0.010x |
|
Kleannara Co Ltd
KO:004545
|
0.034x |
|
Unique Optical Industrial Co Ltd
TWO:3441
|
0.072x |
|
51Talk Online Education Group
NYSE MKT:COE
|
-0.378x |
|
It's Skin Co Ltd
KO:226320
|
0.019x |
Annual Cash Flow Conversion Efficiency for Euroapi SAS (2019–2025)
The table below shows the annual cash flow conversion efficiency of Euroapi SAS from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Euroapi SAS.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €788.00 Million ≈ $921.25 Million |
€125.50 Million ≈ $146.72 Million |
0.159x | +27.45% |
| 2024-12-31 | €983.50 Million ≈ $1.15 Billion |
€122.90 Million ≈ $143.68 Million |
0.125x | +2173.08% |
| 2023-12-31 | €927.70 Million ≈ $1.08 Billion |
€5.10 Million ≈ $5.96 Million |
0.005x | -86.38% |
| 2022-12-31 | €1.11 Billion ≈ $1.30 Billion |
€44.80 Million ≈ $52.38 Million |
0.040x | -42.91% |
| 2021-12-31 | €1.01 Billion ≈ $1.18 Billion |
€71.50 Million ≈ $83.59 Million |
0.071x | -27.75% |
| 2020-12-31 | €989.40 Million ≈ $1.16 Billion |
€96.80 Million ≈ $113.17 Million |
0.098x | +185.41% |
| 2019-12-31 | €1.02 Billion ≈ $1.19 Billion |
€34.90 Million ≈ $40.80 Million |
0.034x | -- |
About Euroapi SAS
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that uses solid phase chemistry;… Read more